Laura Lawrence

Laura Lawrence's 30 Years of Experience

Laura Lawrence boasts over 30 years of combined experience in pharmaceutical research and clinical operations. Her extensive tenure in the industry has equipped her with a deep understanding of the complexities involved in drug development and clinical trials. This wealth of experience has allowed her to lead teams and manage projects that have significantly contributed to advancements in medical science, particularly in the fields of hematology-oncology and antibiotics.

Laura Lawrence's Role at Cellectar Therapeutics

As a Clinical Operations Leader at Cellectar Therapeutics, Laura Lawrence focused on rare hematology-oncology diseases. In this role, she was responsible for overseeing clinical trials and ensuring that they met regulatory standards and scientific rigor. Her leadership in this niche field has been instrumental in pushing forward the development of treatments for conditions that often lack adequate therapeutic options.

Laura Lawrence's Tenure at Melinta Therapeutics and Rib-X Pharmaceuticals

Laura Lawrence spent 14 years at Melinta Therapeutics and Rib-X Pharmaceuticals, where she played a pivotal role in advancing an antibiotic for acute skin infections and bacterial pneumonia. Her work in clinical operations was crucial in navigating the drug through various phases of clinical trials, ultimately aiming to bring effective treatments to market. This period in her career highlights her expertise in infectious diseases and her commitment to improving patient outcomes.

Laura Lawrence's Early Career and Education

Laura Lawrence began her career as a Research Scientist at R.W. Johnson PRI, which laid the foundation for her subsequent roles in drug discovery and clinical operations. She holds a bachelor's degree in biochemistry from North Carolina State University, providing her with the scientific knowledge necessary for her work in pharmaceuticals. Her early years also included four years of drug discovery research in microbiology at Rib-X Pharmaceuticals and five years at Bristol Myers Squibb, where she honed her skills in identifying and developing new therapeutic agents.